Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients of all ages
suffering from respiratory distress, today announced that its management
team will be presenting at the William Blair 39th Annual Growth Stock
Conference on Wednesday, June 5th at the Loews Chicago Hotel
in Chicago, Illinois.

Vapotherm is scheduled to present at 3:20pm Central Time. The
presentation will be accessible via a live webcast at:

A webcast replay of the presentation will be available for 90 days
following the presentation in the Event Archive section of Vapotherm’s
Investor website at

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer
and manufacturer of advanced respiratory technology based in Exeter, New
Hampshire, USA. The company develops innovative, comfortable,
noninvasive technologies for respiratory support of patients with
chronic or acute breathing disorders. Over 1.8 million patients have
been treated with Vapotherm Hi-VNI Technology. For more information,

Hi-VNI® Technology is mask-free noninvasive ventilation for
spontaneously breathing patients and a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It
allows for the fast, safe treatment of undifferentiated respiratory
distress with one user-friendly tool. Hi-VNI Technology’s mask-free
interface delivers optimally conditioned breathing gases, making it
comfortable for patients and reducing the risks and care complexities
associated with mask therapies. While being treated, patients can talk,
eat, drink and take oral medication.

Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of its
Vapotherm intends to use this website as a means of disclosing material,
non-public information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should monitor
the Investor Relations section of Vapotherm’s website, in addition to
following Vapotherm’s press releases, Securities and Exchange Commission
filings, public conference calls, presentations and webcasts. The
information contained on, or that may be accessed through, Vapotherm’s
website is not incorporated by reference into, and is not a part of,
this document.


Investor Relations Contact: Mark Klausner or Mike Vallie,
Westwicke, an ICR Company,,

error: Content is protected !!